Evidence map›Paper›PMID 39758976›Full record

ReviewAdvances in radiation oncology2025

The Burden of Insurance Prior Authorization on Cancer Care: A Review of Evidence From Radiation Oncology.

Jayden Gracie, Rachel Jimenez, Karen M Winkfield

Abstract readReview
In one paragraph

Review in Advances in radiation oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Jayden GracieDepartment of Radiation Oncology, Vanderbilt University School of Medicine, Nashville, Tennessee.
Rachel JimenezDepartment of Radiation Oncology, Massachusetts General Hospital, Boston, Massachusetts.
Karen M WinkfieldDepartment of Radiation Oncology, Vanderbilt University School of Medicine, Nashville, Tennessee.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: Despite its high cost-effectiveness, radiation oncology faces the greatest prior authorization (PA) burden of any medical specialty. Insurance denials and resulting treatment delays have been documented across several treatment modalities, including stereotactic body radiation, intensity modulated radiation, and proton therapy. Although insurance companies suggest that PA is intended to control health care spending and ensure the implementation of evidence-based practice, the number of radiation treatment plans reviewed by the PA process that result in changes is quite low. Yet, the cost to patients, providers, and the health care system is rising.The increased administrative work required to address the appeal process, including the development of radiation plan comparisons, results in lost productivity of radiation staff and increased clinic costs that are not currently reimbursed. Treatment delays from PA may elevate patient anxiety and affect their ability to enroll in clinical trials, resulting in decreased quality of care. As a result of possible harm to patients, the Centers for Medicare and Medicaid Services developed a ruling that mandates increased transparency of insurers' requirements, decreased allowable time for arriving at PA decisions, and a more efficient electronic communication system to address the time and resource burden of PA. Methods and Materials: This article summarizes key discussions from the literature and provides recommendations to help mitigate insurance PA strain. Results: These recommendations broadly address the following key areas: (1) omission of PA for routine care and clinical trials, (2) implementation of efficient, streamlined electronic peer-to-peer communication, (3) increased transparency of insurance requirements and rationale for denials, and (4) decreased time allowances for PA decisions. Conclusions: Policy reform focused on evidence-driven treatment coverage, reduction of the proportion of cases requiring PA, and a simplified, timely insurance appeal process is necessary to ensure optimal cancer care for patients requiring radiation therapy as part of their cancer journey.

Identifiers

PMID39758976
PMCPMC11699354

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.